| This week's sponsor is Premier Research. | |  | Taking the Fight to Rare Cancers
Beating rare cancers demands expertise in oncology and rare diseases. Our white paper shows how adaptive design, study committees, and cross-industry cooperation are fueling real progress. Premier Research. Built for biotech. |
Today's Rundown Featured Story | | | Monday, August 26, 2019 As fairy-tale biotech stories go, this is up there: You’re a small, ambitious startup getting a healthy $30 million series A. Fast-forward less than a year, and you’re being bought for a quarter of billion dollars upfront. |
|
|
Top Stories Monday, August 26, 2019 A phase 3 trial of The Medicines Company’s cholesterol-lowering drug inclisiran has met its primary endpoint. The company is yet to share the efficacy data that will show whether inclisiran can compete with other PCSK9 drugs. Monday, August 26, 2019 Mark Schoenebaum, the longtime biopharma analyst admired as much for his personality as for his work, died over the weekend, wrote Umer Raffat, an Evercore ISI colleague that Schoenebaum mentored, on Sunday evening. The cause of death wasn’t specified, but he had taken medical leave from Evercore in 2016 and left the firm in 2017. Monday, August 26, 2019 Aerie Pharmaceuticals has named Luis Vargas as medical director for medical affairs. The appointment puts Vargas in charge of medical affairs organizational planning and operational matters at the eye disease company. Monday, August 26, 2019 Patient groups in the U.K. are getting fed up with what they see as a pushback from the very organization set up to try to combat the issue of clinical trial transparency. Monday, August 26, 2019 ADC Therapeutics and Freenome—two companies coming off successful venture rounds and expansions, recently bringing in over $260 million between them—have launched a new collaboration to develop biomarkers and tests for ADC’s lead cancer therapy. Monday, August 26, 2019 Looks like Amgen might not be buying Alexion after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel, by snatching up Celgene’s Otezla for $13.4 billion. | This week's sponsor is ExL Events. | |  | |
Enrollment Showcase | | | October 23-25, 2019 | Chicago, IL | Presented by Biotech Primer BioImmersion: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. Register today! |
|
|
Resources Sponsored by: Alexander Group From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. |
|
